Daré Bioscience, Inc. (DARE): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a biopharmaceutical company tackles unmet needs in women's health? Daré Bioscience, with a market cap of around $67.98 million as of April 2024, is making strides in this area. Keep reading to explore Daré Bioscience's journey, from its foundational mission to its innovative products like XACIATO™ and potential revenue streams.

Daré Bioscience, Inc. (DARE) History

Daré Bioscience Founding Timeline

Year established

Daré Bioscience was established in 2015.

Original location

The company is headquartered in San Diego, California.

Founding team members

While specific details about all founding team members are not widely publicized, Sabrina Martucci Johnson is a prominent figure as the company's President and CEO. She has been instrumental since the company’s inception.

Initial capital/funding

Information on the precise initial capital or funding at the very start of Daré Bioscience is not explicitly detailed in the available resources. However, the company has utilized various financing strategies, including public offerings, to support its operations and development programs.

Daré Bioscience's Evolution Milestones

Daré Bioscience's Transformative Moments

• Reverse Merger with Cerulean Pharma (2017): This merger was a pivotal moment, providing the company with a public listing and the necessary capital to aggressively pursue its women's health initiatives.
• FDA Approval of XACIATO™ (2022): Receiving FDA approval for XACIATO™ was a crucial achievement, validating the company's research and development capabilities and paving the way for commercialization.
• Strategic Collaboration and Licensing Agreements: Forming key partnerships and licensing agreements with established companies like Organon significantly expanded the reach and impact of Daré's products, enhancing its market position and revenue potential.
• Focus on Unmet Needs: Prioritizing the development of products that address unmet needs in women's health has distinguished Daré Bioscience, fostering innovation and market relevance.

To gain more in-depth insights, check out: Exploring Daré Bioscience, Inc. (DARE) Investor Profile: Who’s Buying and Why?

Daré Bioscience, Inc. (DARE) Ownership Structure

Understanding a company's ownership structure is crucial for investors and stakeholders, as it reveals who has control and influence over its decisions. The following sections break down the ownership of Daré Bioscience, Inc., providing insights into its current status, ownership distribution, and key leadership figures.

Daré Bioscience, Inc.'s Current Status

Daré Bioscience, Inc. is a publicly traded company. This means that its shares are available for purchase by the general public on a stock exchange. As a public company, Daré Bioscience is subject to regulatory requirements, including financial reporting and disclosures, providing transparency to investors.

Daré Bioscience, Inc.'s Ownership Breakdown

The ownership of Daré Bioscience is distributed among various shareholders, including institutional investors, individual investors, and company insiders. The following table provides an overview of the ownership breakdown:

Daré Bioscience, Inc.'s Leadership

The leadership team at Daré Bioscience is responsible for setting the strategic direction of the company and overseeing its operations. As of April 2025, key members of the leadership team include:

• Sabrina Martucci Johnson: President and Chief Executive Officer
• Lisa Walters-Hoffert: Chief Financial Officer
• David ото: Chief Commercial Officer

These individuals, along with other members of the executive team, bring a wealth of experience and expertise to Daré Bioscience, guiding the company in its mission to develop and commercialize innovative products for women's health. For more insights into the company's goals, explore Mission Statement, Vision, & Core Values of Daré Bioscience, Inc. (DARE).

Daré Bioscience, Inc. (DARE) Mission and Values

Daré Bioscience is dedicated to identifying, developing, and marketing innovative products for women's health. The company aims to improve women's lives by addressing unmet needs in areas such as contraception, vaginal health, and sexual health.

Daré Bioscience's Core Purpose

Official mission statement

Daré Bioscience's mission statement reflects its commitment to women's health:

• To identify, develop and bring to market innovative products and therapies that improve women’s health, primarily in the areas of contraception, vaginal health, and sexual health.
• Focuses on addressing unmet needs and expanding treatment options for women.
• Committed to clinical and regulatory excellence, ensuring products are safe and effective.

Vision statement

While a specific vision statement may not be explicitly publicized, the vision can be inferred from their actions and goals:

• To be a leader in women's health innovation, recognized for its contributions to improving women's lives through novel products and therapies.
• Aspires to create significant value for its shareholders by successfully developing and commercializing its portfolio of women's health products.
• To foster a culture of innovation, collaboration, and excellence, attracting and retaining top talent in the industry.

Company slogan/tagline

The company's slogan or tagline is not explicitly available, the essence of their work can be understood through their commitment:

• Focus on innovation in women's health.
• Dedication to addressing unmet needs.
• Commitment to improving women's lives.

Further insights into the company's performance and financial stability can be found at Breaking Down Daré Bioscience, Inc. (DARE) Financial Health: Key Insights for Investors.

Daré Bioscience, Inc. (DARE) How It Works

Daré Bioscience is a biopharmaceutical company focused on developing and marketing innovative products for women's health. They operate by identifying, developing, and bringing to market solutions that address unmet needs in areas such as contraception, vaginal health, and fertility.

Daré Bioscience's Product/Service Portfolio

Daré Bioscience's Operational Framework

Daré Bioscience operates through a strategic framework that integrates product development, clinical trials, regulatory approvals, and commercial partnerships. Their operational activities include:

• Product Development: Identifying and acquiring promising women's health technologies or product candidates.
• Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their product candidates. For instance, the DARE-LARC1 program is set to begin a pivotal Phase 3 clinical trial in the first half of 2025, pending regulatory feedback.
• Regulatory Approvals: Pursuing regulatory approvals from agencies like the FDA to market their products.
• Commercialization: Establishing commercial partnerships or building their own sales and marketing capabilities to launch and sell approved products.
• Lifecycle Management: Continually assessing and optimizing their product portfolio to maximize value and address evolving market needs.

A key aspect of their operational framework involves strategic collaborations and out-licensing agreements to maximize the reach and impact of their products. For example, they have partnered with Organon for the commercialization of XACIATO™ in the U.S. Exploring Daré Bioscience, Inc. (DARE) Investor Profile: Who’s Buying and Why?

Daré Bioscience's Strategic Advantages

Daré Bioscience has several strategic advantages that contribute to its success in the competitive biopharmaceutical industry:

• Focus on Women's Health: Specializing in women's health allows them to develop deep expertise and understanding of this market.
• Innovative Products: Developing differentiated products that address unmet needs provides a competitive edge.
• Strategic Partnerships: Collaborating with larger pharmaceutical companies can accelerate product development and commercialization.
• Experienced Management Team: A strong management team with experience in drug development and commercialization is crucial for success.
• Intellectual Property: Protecting their products with patents and other intellectual property rights provides a competitive advantage.

These advantages enable Daré Bioscience to effectively navigate the complexities of the biopharmaceutical industry and deliver value to its stakeholders.

Daré Bioscience, Inc. (DARE) How It Makes Money

Daré Bioscience, Inc. primarily generates revenue through the development and commercialization of innovative products for women's health. This includes licensing agreements, collaborations, and potential direct sales of approved products.

Daré Bioscience, Inc.'s Revenue Breakdown

Daré Bioscience, Inc.'s Business Economics

Daré Bioscience operates with a focus on addressing unmet needs in women's health, aiming to develop and bring to market novel therapies. Their business model relies on strategic collaborations and out-licensing agreements to fund and advance their product pipeline. Key economic aspects include:

• Strategic Partnerships: Collaborations with larger pharmaceutical companies are crucial for funding clinical trials and gaining regulatory approvals.
• Out-Licensing: Daré Bioscience seeks to out-license its products to generate revenue once they reach certain developmental milestones or achieve regulatory approval.
• Focus on Innovation: By concentrating on innovative therapies, Daré aims to capture niche markets with high potential returns.
• Cost Management: Efficient management of research and development expenses is vital, given the high costs associated with drug development.

Daré Bioscience, Inc.'s Financial Performance

As a development-stage company, Daré Bioscience's financial performance is characterized by significant R&D expenses and reliance on funding through collaborations, licensing, and capital markets. Here are some key points:

• R&D Expenditure: A substantial portion of the company's expenses is dedicated to research and development activities, reflecting its focus on advancing its product pipeline. In 2024, R&D expenses totaled $23.9 million.
• Operating Expenses: Operating expenses consist primarily of R&D and general and administrative costs. For the year 2024, total operating expenses were $32.2 million.
• Net Loss: Daré Bioscience typically experiences net losses as it invests heavily in its pipeline without generating substantial product revenue. The net loss for the year ended December 31, 2024, was approximately $31.7 million, or $2.41 per share.
• Cash Resources: Maintaining adequate cash reserves is essential for funding ongoing operations and clinical trials. As of December 31, 2024, Daré Bioscience had cash and marketable securities of $21.5 million.

For more insights into Daré Bioscience, Inc., check out: Exploring Daré Bioscience, Inc. (DARE) Investor Profile: Who’s Buying and Why?

Daré Bioscience, Inc. (DARE) Market Position & Future Outlook

Daré Bioscience is strategically positioned to address unmet needs in women's health, with a focus on innovative therapies. The company's future outlook is shaped by its ability to navigate regulatory pathways, secure partnerships, and successfully commercialize its product candidates.

Competitive Landscape

Opportunities & Challenges

Industry Position

Daré Bioscience occupies a niche position within the women's health market, focusing on innovative solutions that address unmet needs. Key aspects of its industry standing include:

• Pipeline Focus: Emphasis on developing novel therapies, particularly in contraception, vaginal health, and sexual dysfunction.
• Strategic Partnerships: Collaborations to advance product development and commercialization efforts.
• Market Differentiation: Aiming to offer alternatives to traditional hormonal treatments.

To gain more insights into the investors behind Daré Bioscience, explore: Exploring Daré Bioscience, Inc. (DARE) Investor Profile: Who’s Buying and Why?